Stephen Hoge - Apr 25, 2022 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
President
Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Stock symbol
MRNA
Transactions as of
Apr 25, 2022
Transactions value $
-$2,745,597
Form type
4
Date filed
4/26/2022, 04:07 PM
Previous filing
Apr 14, 2022
Next filing
May 4, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Options Exercise $54.5K +5K +0.31% $10.90* 1.63M Apr 25, 2022 Direct F1
transaction MRNA Common Stock Options Exercise $54.5K +5K +0.31% $10.90* 1.63M Apr 25, 2022 Direct F1
transaction MRNA Common Stock Options Exercise $9.9K +10K +0.61% $0.99* 1.64M Apr 25, 2022 Direct F1
transaction MRNA Common Stock Sale -$1.46M -10.4K -0.63% $140.06 1.63M Apr 25, 2022 Direct F1, F2
transaction MRNA Common Stock Sale -$70.9K -500 -0.03% $141.80 1.63M Apr 25, 2022 Direct F1, F3
transaction MRNA Common Stock Sale -$86.2K -602 -0.04% $143.16 1.63M Apr 25, 2022 Direct F1, F4
transaction MRNA Common Stock Sale -$152K -1.05K -0.06% $144.15 1.63M Apr 25, 2022 Direct F1, F5
transaction MRNA Common Stock Sale -$334K -2.3K -0.14% $145.39 1.63M Apr 25, 2022 Direct F1, F6
transaction MRNA Common Stock Sale -$132K -900 -0.06% $146.31 1.63M Apr 25, 2022 Direct F1, F7
transaction MRNA Common Stock Sale -$132K -900 -0.06% $147.14 1.63M Apr 25, 2022 Direct F1, F8
transaction MRNA Common Stock Sale -$88.9K -600 -0.04% $148.24 1.63M Apr 25, 2022 Direct F1, F9
transaction MRNA Common Stock Sale -$173K -1.16K -0.07% $149.33 1.62M Apr 25, 2022 Direct F1, F10
transaction MRNA Common Stock Sale -$223K -1.49K -0.09% $150.32 1.62M Apr 25, 2022 Direct F1, F11
transaction MRNA Common Stock Sale -$15.1K -100 -0.01% $150.95 1.62M Apr 25, 2022 Direct F1
holding MRNA Common Stock 4.12K Apr 25, 2022 By Valhalla, LLC
holding MRNA Common Stock 152K Apr 25, 2022 By Trust F12

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -5K -5.16% $0.00 92K Apr 25, 2022 Common Stock 5K $10.90 Direct F1, F13
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -5K -5.44% $0.00 87K Apr 25, 2022 Common Stock 5K $10.90 Direct F1, F13
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -10K -21.08% $0.00 37.4K Apr 25, 2022 Common Stock 10K $0.99 Direct F1, F13
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $139.92 to $140.77. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $141.43 to $142.29. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $142.52 to $143.51 Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F5 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $143.60 to $144.56. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F6 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $144.81 to $145.77. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F7 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $145.85 to $146.83. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F8 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $146.89 to $147.43. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F9 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $147.91 to $148.63. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F10 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $148.93 to $149.77. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F11 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $149.94 to $150.91. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F12 These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F13 This option is fully vested and exercisable.